[go: up one dir, main page]

GB202107182D0 - Nanoparticle delivery system for production of engineered extracellular vesicles - Google Patents

Nanoparticle delivery system for production of engineered extracellular vesicles

Info

Publication number
GB202107182D0
GB202107182D0 GBGB2107182.4A GB202107182A GB202107182D0 GB 202107182 D0 GB202107182 D0 GB 202107182D0 GB 202107182 A GB202107182 A GB 202107182A GB 202107182 D0 GB202107182 D0 GB 202107182D0
Authority
GB
United Kingdom
Prior art keywords
production
delivery system
extracellular vesicles
nanoparticle delivery
engineered extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2107182.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evox Therapeutics Ltd
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Priority to GBGB2107182.4A priority Critical patent/GB202107182D0/en
Publication of GB202107182D0 publication Critical patent/GB202107182D0/en
Priority to PCT/EP2022/063655 priority patent/WO2022243484A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB2107182.4A 2021-05-19 2021-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles Ceased GB202107182D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2107182.4A GB202107182D0 (en) 2021-05-19 2021-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles
PCT/EP2022/063655 WO2022243484A1 (en) 2021-05-19 2022-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2107182.4A GB202107182D0 (en) 2021-05-19 2021-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles

Publications (1)

Publication Number Publication Date
GB202107182D0 true GB202107182D0 (en) 2021-06-30

Family

ID=76550772

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2107182.4A Ceased GB202107182D0 (en) 2021-05-19 2021-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles

Country Status (2)

Country Link
GB (1) GB202107182D0 (en)
WO (1) WO2022243484A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117126888A (en) * 2023-06-21 2023-11-28 安徽省立医院(中国科学技术大学附属第一医院) Extracellular vesicle delivery platform loaded with proteins or polypeptides and its application
WO2025054143A2 (en) * 2023-09-04 2025-03-13 Mercury Bio, Inc. Protein sorting motifs for the packaging of therapeutic proteins into yeast extracellular vesicles for targeted delivery to cells and blood

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
EP3697447A4 (en) * 2017-10-16 2021-08-25 Aadigen, LLC Peptides and nanoparticles for intracellular delivery of mrna
GB201800921D0 (en) * 2018-01-19 2018-03-07 Evox Therapeutics Ltd Intracellular delivery of target silencing technology
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
GB201809622D0 (en) * 2018-06-12 2018-07-25 Evox Therapeutics Ltd Engineering extracellular vesicles for affinity purification

Also Published As

Publication number Publication date
WO2022243484A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
SG11202109702QA (en) Extracellular vesicles for vaccine delivery
GB202107182D0 (en) Nanoparticle delivery system for production of engineered extracellular vesicles
EP3727351A4 (en) MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY
MX2018011202A (en) Therapeutic membrane vesicles.
EP2700399A4 (en) DRUG DELIVERY PARTICLES AND METHOD FOR PRODUCING THE SAME
EP4288034A4 (en) Targeted extracellular vesicles for delivery of therapeutics
EP3471670B8 (en) Apparatus to form entry bleb for subretinal delivery of therapeutic agent
EP3250706A4 (en) Extracellular vesicles for agent delivery
SG11201401658SA (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
EP2707146A4 (en) NOZZLES FOR NASAL MEDICATION DELIVERY
MX2015001561A (en) Vesicles which include epidermal growth factor and compositions that contain same.
MX368844B (en) Imidazoline derivatives, preparation methods thereof, and their applications in medicine.
EP2968881B8 (en) Apparatus for delivery of medication to the brain to treat neurological conditions
ZA201501372B (en) Production of soluble protein products from hemp ("h701")
MX352176B (en) Process for producing inorganic particulate material.
IL299634A (en) Process for the manufacturing of protein-associated extracellular vesicles
IL286122A (en) Method for hydrolysis of lactic acid for aerosol delivery device
UA111434C2 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
IT1399862B1 (en) VERTICAL AXIS MACHINE FOR THE PRODUCTION OF FILTER BAGS WITH INFUSION PRODUCTS
EP2842545A4 (en) METHOD FOR PRODUCING AN AQUEOUS DISPERSION OF NANOPARTICLES OF MEDICAMENT AND USE THEREOF
TN2014000532A1 (en) N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
MX344845B (en) Chocolate production method and apparatus.
MX2016006738A (en) Process for producing inorganic particulate material.
EP2877575A4 (en) PROCESS FOR PRODUCING RECOMBINANT HUMAN ALPHA-GALACTOSIDASE A
IN2014DN02060A (en)

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)